back to search abstracts online

Sunday January 30,2000	Monday January 31, 2000	Tuesday February 1, 2000	Wednesday February 2, 2000
Abstract 428. Effects of In Vivo CD8-Depletion on the Control of Virus Replication in Rhesus Macaques Immunized with a Live, Attenuated SIV Vaccine and Protected from Pathogenic SIV Challenge Abstract 429. Protection of Macaques against Vaginal Transmission of a Pathogenic HIV-1/SIV Chimeric Virus (SHIV) by Passive Infusion of Neutralizing Antibodies Abstract 430. Recombinant Modified Vaccinia Ankara (MVA)-Elicited SIV Gag-Specific Cytotoxic T Lymphocytes in Rhesus Monkeys Abstract 431. Second-Generation Enhanced DNA, Alphavirus, and Adjuvanted Protein Vaccine Approaches Stimulate Potent Immune Responses against HIV Antigens Abstract 432. Novel Alphavirus Vaccine Vectors for Efficient Gene Delivery to Dendritic Cells Abstract 433. HIV Gag Encoding RNA Transfected DCs Induce a Primary Immune Response In Vitro Abstract 434. In Vivo T Cell Priming in Rhesus Macaques by Reinjected Immature and Mature Dendritic Cells Bearing Soluble or Recombinant Viral Vector-Encoded Antigens Abstract 435. HIV Replication in Human, Adult Microglia Varies with Activation State Abstract 436. Flow Cytometric Analysis of Cerebrospinal Fluid (CSF) T-Lymphocytes in HIV Infection: Feasibility and Initial Cross-Sectional and Longitudinal Observations Abstract 437. Brain-Derived HIV-1 A and D Clade gp120 Sequences Display Recombination Events and High Molecular Diversity Abstract 438. Mapping the Mechanism(s) of SDF-1a-Induced Neuronal Dysfunction Abstract 439. HIV-1 Tat Induction of Matrix Metalloproteinases Causes Neuronal Damage Abstract 440. Antiretroviral Therapy (ART) Induces Changes in Chemokines That Correlate with Improvements in Cognitive Function and HIV RNA Abstract 441. Amelioration of Neurotoxic Effects of HIV Envelope Protein Gp120 by Fibroblast Growth Factor-1: A Strategy For Neuroprotection Abstract 442. The Effect of Genotypic Resistance on the Cerebrospinal Fluid Virological Response to Highly Active Antiretroviral Therapy Abstract 443. Trafficking of T Lymphocytes and Virions through the Thoracic Duct of SIV-Infected Rhesus Macaques Abstract 444. Origin of FDC-Associated Virions Abstract 445. Identification of Two Novel Domains of SIVmac239 Nef Important for Activation of and Association with the p21-Activated Kinase (PAK) Abstract 446. HIV-1 Nef-Mediated Downregulation of CD4 Closely Correlates with Nef Enhancement of Viral Pathogenesis Abstract 447. Elimination of CD4+ T Cells In Vivo Is Determined by CCR5 Coexpression and the State of Cell Activation in Early SIV Infection Abstract 448. CCR5 Haplotypes Associated with Enhanced or Reduced Transmission of HIV-1 from Mother-to-Child Abstract 449. Polymorphism in RANTES Chemokine Promoter Affects HIV-1 Disease Progression in Japanese and Distributes Differently in Asians, Africans, and Caucasians Abstract 450. Up-Regulation of Type 1 Interferon-Inducible Genes After HIV-1 Rebound in Persons Terminating HAART Abstract 451. Patterns of Plasma HIV RNA Responses in Antiretroviral Treatment Success and Failure Abstract 452. CCR5 D32 Deletion and Response to HAART in HIV-1-Infected Patients Abstract 453. Improvement in CD4 T-Cell Counts Despite Virologic Treatment Failure: Role of Thymic Output Abstract 454. Association of Viral Load, CD4 Cell Count, and Treatment with Clinical Progression in HIV Patients with Very Low CD4 Cell Counts: The EuroSIDA Cohort Abstract 455. Pharmacodynamics (PD) of Indinavir (IDV) in Protease-Naive HIV-Infected Patients Receiving ZDV and 3TC Abstract 456. Randomized Trial of Continued Indinavir (IDV)/ZDV/3TC vs. Switch to IDV/ddI/d4T or IDV/ddI/d4T + Hydroxyurea in Patients with Viral Suppression Abstract 457. Protease Inhibitor Class-Sparing Maintenance Therapy with Abacavir (ABC) + Lamivudine (3TC) + Zidovudine (ZDV) in Patients with Long-Term Suppression of HIV-1 RNA Abstract 458. SITT: A Prospective Trial of Strategic Treatment Interruptions Abstract 459. Pre-AIDS Mortality and Its Association with HIV Disease Progression in Hemophilic Men, Injecting Drug Users, and Homosexual Men Abstract 460. Is HAART Enough? Abstract 461. Mortality in a Prospective Cohort of HIV-Infected Adults Started on a Protease Inhibitor (PI)-Containing Therapy: Standardization to the French General Population Abstract 462. Trends in Fatal Infectious Diseases among Persons Dying of HIV Infection in the Era of HAART Abstract 463. The Changing Spectrum of HIV Mortality: Analysis of 249 Deaths from 1995-1999 Abstract 464. Causes of Death and Factors Associated with AIDS-related Mortality in Seattle-King County, WA Abstract 465. Utilization of Medical Services Is Associated with Survival Among Patients with the Acquired Immunodeficiency Syndrome Abstract 466. African Americans with HIV-Related Pneumocystis carinii Pneumonia (PCP) to Receive High-Quality PCP Care and More Likely to Survive Hospitalizations Abstract 467. Assessing Feasibility of STD Control Interventions for HIV Prevention in the United States Abstract 468. High HIV Seroprevalence Associated with Diagnosis of Gonorrhea or Syphilis in Men Who Have Sex with Men Abstract 469. Rebound of Seminal HIV-1 Viral Load Associated with Sexually Transmitted Diseases (STDs) after Virologic Suppression by Antiretroviral Therapy Abstract 470. Emergence of Primary and Secondary Syphilis among Men Who Have Sex with Men in Chicago and Relationship to HIV Infection Abstract 471. Predictors of Seminal Viral Load (SVL) Suppression in Subjects Starting Antiretroviral Therapy (ART) Abstract 472. Effects of Partner Notification for HIV and Syphilis on Behaviors and Relationships Abstract 473. Primary HIV Infections Associated with Oral Transmission Abstract 474. Epidemiology of HIV Testing Among Tuberculosis Patients in North Carolina Abstract 475. An Assessment of HIV-1 Seroprevalence Trends among TB Clinic Attendants, Blood Donors and the General Population among African Nations Abstract 476. Transfusion-Transmitted Virus (TTV) Infection among Homosexual Men and Injecting Drug Users in Italy: Higher Prevalence Related to HIV Infection Abstract 477. Risk Factors for Hepatitis C Virus (HCV) Infection in a Well-Characterized Long-Term Cohort of Homosexual Men Abstract 478. Rates of Risk Behaviors among U.S. HIV-Positive Blood Donors Abstract 479. European HIV Reporting: First Results and Comparison with AIDS Reporting Abstract 480. Comparing Risk Behaviors between HIV-1-Seropositive Clients and Recent HIV-1 Seroconverters among Illicit Drug Users (IDU's) Receiving HIV Counseling and Testing (C/T) at a Drug Treatment Center (DTC) in NYC from 1994 to 1998 Abstract 481. Risk Factors for Recent HIV-1 Infection Identified by Sensitive/Less-Sensitive EIA Testing at an Anonymous Testing Center in Santos, Brazil Abstract 482. Application of the Sensitive/Less-Sensitive EIA Testing Strategy to Estimate Incidence among Drug Users Admitted to Drug Treatment Abstract 483. Drug Users Participating in Mobile Needle Exchange Report Higher HIV Risk Behaviors Than Those Participating in Pharmacy-Based Needle Exchange Abstract 484. HIV Seroconversion among Injection Drug Users Attending Needle Exchange Programs in Montreal, Quebec, Canada: Before and after 1995 Abstract 485. High-Risk Behaviors In and Out of Incarcerated Settings for African-American Men Treated for HIV at 3 Los Angeles Public Medical Centers Abstract 486. Incarceration and Heterosexual HIV Infection among Rural African Americans Abstract 487. A Cluster of HIV-Infected Adolescents and Young Adults in Rural Mississippi (MS) Abstract 488. Sensitive/Less-Sensitive HIV Testing Strategy to Identify a High-Risk Heterosexual Population in Brazil Abstract 489. Late Seroconversion in HIV ‘Resistant’ Nairobi Prostitutes Is Associated with a Preceding Decrease in HIV Exposure Abstract 490. Molecular Evidence for Homosexual Transmission of HIV-2 in a Cluster of Older Men in Gipuzkoa, Spain Abstract 491. Pediatric and Adolescent HIV Prophylaxis after Sexual Assault Abstract 492. Demand for Post-Sexual-Exposure Chemoprophylaxis for the Prevention of HIV Infection in Brazil Abstract 493. Antiretroviral Postexposure Prophylaxis in Italy Abstract 494. Spare Postexposure Prophylaxis with Immediate HIV Testing of the Source Patient Abstract 495. Validation of an Expert System (ES) for Management of HIV Occupational Postexposure Prophylaxis (PEP) Abstract 496. Prevalence of Drug-Resistant HIV-1 in Patients Who Are the Source of Occupational Exposures to Health Care Workers Abstract 497. Host and Viral Factors Influence CCR5 Receptor Blockade Abstract 498. TAK-779, a Specific Inhibitor of HIV-1 Entry, Binds within a Pocket Formed by the Trans-Membrane Domains of CCR5 Abstract 499. Dual-Tropic Recombinant Chimeric Chemokines Directed against Both M-Tropic (R5) and T-Tropic (X4) HIVs Abstract 500. Strong In Vitro Synergy Observed between the Fusion Inhibitor T-20 and a CXCR4 Blocker AMD-3100 Abstract 501. Combined Effect of AOP-RANTES and Met-SDF-1beta in Inhibiting Infections by PHI Viral Isolates In Vitro Abstract 502. Effects of Peptide-Induced Humoral Responses and Preexisting Antibodies in Nonhuman Primates and HIV-Infected Patients Following Chronic Administration of T-20. Abstract 503. Dendrimers Can Inhibit the Replication of Human Immunodeficiency Virus (HIV) by Interfering with Both Virus Adsorption and Later Steps (Reverse Transcriptase/Integrase) in the Virus Replicative Cycle Abstract 504. BMS-232632: A Summary of Multiple Dose Pharmacokinetic, Food Effect and Drug Interaction Studies in Healthy Subjects Abstract 505. Highly Polar, Water-Soluble Prodrugs of Amprenavir: A New Approach toward a More Compact Dosing Regimen Abstract 506. Pharmacokinetics and Tolerability of MK-944A, a Combination of a New HIV Protease Inhibitor with Indinavir, in Phase I Studies Abstract 507. Lack of Development of Drug Resistance during Short-Term Clinical Evaluation of Quinoxaline-Class NNRTI GW420867X Abstract 508. A Phase IB Study of (+)-Calanolide A in HIV-1-Infected, Antiretroviral Therapy Naive Patients Abstract 509. The Synergistic Inhibition of HIV-1 With Nucleoside Analogs Combined With A Natural Product, Resveratrol Abstract 510. Preliminary Results of a Randomized Multicenter Study Comparing Combivir (ZDV/3TC) plus Nelfinavir or Nevirapine in HIV-Infected Naive Patients (COMBINE Study) Abstract 511. Indinavir (IDV) + Zidovudine (ZDV) + Lamivudine (3TC) in Treatment-Naive Patients with >500 CD4 Cells/mm3: 48-Week Follow-Up Abstract 512. A Dose-Finding Study of Once-Daily Indinavir/Ritonavir plus Combivir in HIV-Infected Patients Abstract 513. Durable HIV Suppression and Tolerability with Efavirenz (EFV) + Indinavir (IDV): Results at 132 Weeks (Study 003-Cohort IV) Abstract 514. 24-Week Results of the Antiviral Activity, Safety, and Tolerability of Emivirine (EMV, Coactinon) + Stavudine (d4T, Zerit) + Didanosine (ddI, Videx) in Treatment-Naive HIV-Infected Patients (MKC-302) Abstract 515. ABT-378/ritonavir (ABT-378/r) in Antiretroviral Naive HIV+ Patients: 72 Weeks Abstract 516. Sex Differences in the Selection of Thymidine Analog Regimen Therapy Trials (START I and START II) Abstract 517. Factors Predictive of Durable HIV Suppression in Randomized Double-Blind Trial with Nevaripine (NVP), Zidovudine (ZDV), and Lamivudine (3TC) in Treatment-Naive (ARV-n) Patients with Advanced AIDS Abstract 518. A Pilot Study of FTC + ddI + Efavirenz in Treatment-Naive HIV-Infected Adult: A Potent and Convenient Once-a-Day HAART (ANRS 091 Trial) Abstract 519. Meta-Analysis of Efficacy of Triple Combination Therapy in Antiretroviral-Naive HIV-1-Infected Adults Abstract 520. Estimates of Length of Treatment Required to Suppress Plasma Viremia below 50 Copies/mL in HIV-1-Infected Adults Abstract 521. Early Versus Late Initiation of Indinavir (IDV) in Combination with Zidovudine (ZDV) and Lamivudine (3TC) in HIV-1-Infected Adults Abstract 522. Start HAART Early (CD4 > 350 Cells/mm3 or Later? Evidence for Greater Effectiveness if Started Early Abstract 523. When Should We Start? Use of Markov Modeling and Decision Analysis to Evaluate the Long-Term Implications of Antitretroviral Therapy Abstract 524. HIV-NAT 001.1: Randomized, Open-Label Study Comparing d4T/ddI/Saquinavir-SGC vs. CombivirR/Saquinavir-SGC in a ZDV/ddC-Pretreated Thai Population Abstract 525. Continued Lamivudine (3TC) vs. Delavirdine (DLV) in Combination with Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Patients: 48-Week Follow-Up of ACTG 370 Abstract 526. Indinavir (IDV), Nevirapine (NVP), Stavudine (d4T) and Lamivudine (3TC) for Amprenavir (APV)-Experienced Subjects—ACTG 373 Abstract 527. Ritonavir/Saquinavir Versus Ritonavir/Saquinavir/Stavudine in HIV-1-Infected Individuals during 48 Weeks: The Effect of Treatment Intensification Abstract 528. Adefovir Dipivoxil (ADV) 60 mg and 120 mg in Combination Regimens for PI-Naive Patients Abstract 529. Randomized Trial of Abacavir (ABC) in Combination with Indinavir (IDV) and Efavirenz (EFV) in HIV-Infected Patients (Pts) with Nucleoside Analog Experience (NRTI Exp) Abstract 531. ACTC 364- Nelfinavir (NFV) and/or Efavirenz (EFV) in Combination with New NRTIs in Nucleoside Experienced Subjects (Subj): Week-48 Ultrasensitive (US) HIV RNA Results Abstract 532. ABT-378/Ritonavir (ABT-378/r) Suppresses HIV RNA to <400 Copies/ml in 84% of PI-Experienced Patients at 48 Weeks Abstract 533. Three-Year Follow-Up and Conditional Outcomes Survival Analysis of Ritonavir (RTV) plus Saquinavir (SQV) Therapy in HIV Infection Abstract 534. Ritonavir Intensification in Indinavir Recipients with Detectable HIV RNA Levels Abstract 535. Potent Antiviral Activity Using Delavirdine and Reduced-Dose Indinavir Combination Therapies: A 48-Week Analysis Abstract 536. Multidrug Rescue Therapy (MDRT) in Two Cohorts of HIV+ Individuals Abstract 538. Risks and Benefits of Replacing Protease Inhibitors by Nevirapine in Patients with Long-Term Successful Triple Combinations Abstract 539. Virological Response to a Second-Line Protease Inhibitor (PI) Regimen: Laboratory Markers and Choice of Treatment Abstract 540. Phase I Trial of the Infusion of Autologous CD3CD28-Costimulated CD4 Cells in HIV-1 Infection Abstract 541. Adoptively Transferred HIV-Specific Cytotoxic T Lymphocytes Traffic to Lymph Nodes and Localize in Sites of HIV Replication, Granzyme-B Expression, and Cell Death Abstract 542. Antiretroviral Activity and Tolerability of PEG-Interferon a-2b in Patients on Stable Background Therapy: Results of a Phase I/II Study Abstract 543. ILSTIM (ANRS 082)-A Randomized Comparative Open-Label Study of Interleukin w(IL2) in Patients with CD4 <200/mm3 Despite Effective HAART Abstract 544. Aggressive HAART + IL-2 Is Unable to Induce HIV Remission in Early-Stage Disease after 18 Months Abstract 545. Effect of HAART and Immune-Based Strategies in HIV-1-Infected Antiretroviral-Naive Adults Abstract 546. Effect of T-Cell Activation under HAART on the Long-Lived Reservoir of HIV-Infected Quiescent CD4+ T Cells: Implications for Treatment, Homeostasis, and Pathogenesis in HIV Infection Abstract 547. Induction and Elimination of Latent HIV via T Cell Activation Abstract 548. Inhibition of Drug-Resistant HIV-1 by Genetic Antivirals Abstract 549. A Novel Retrovirus-Based Transducing Vector That Transduces CD34+ Enriched Leukocytes Abstract 550. Genetically Engineered C-Type Retroviral Vectors Derived from Spleen Necrosis Virus (SNV) Capable of Infecting Quiescent Cells Abstract 551. Efficient Gene Transfer to Hematopoietic Progenitor Cells Using SV40-Derived Vectors Abstract 552. Intervention with Quadruple HAART [Combivir (COM) / Abacavir (ABC) / Amprenavir (APV)] Intervention during Primary HIV-1 Infection (PHI) Is Associated with Rapid Viremia Clearance and Decrease of Immune Activation Abstract 553. Slower HIV Decline after Highly Suppressive Antiretroviral Therapy of Primary Infection as Compared with Chronic Infection Abstract 554. Impact of HAART on Virus Load and Anti-HIV-1 Antibody in Acute HIV-1 Infection Abstract 555. Treatment of Primary HIV-1 Infection with the Combination of Zidovudine/Lamivudine plus Nelfinavir and Randomized to Immediate or Deferred IL-2 Abstract 556. In Subjects with Primay HIV Infection, High Levels of HIV RNA Are Present in Oral Fluids, Genital Secretions, Peripheral Blood, and CNS and Are Rapidly Reduced with Combination Antiretroviral Therapy Abstract 557. Two-Year Decay Characteristics of PBMC-Associated and Tonsilar HIV RNA and DNA in Acutely HIV-Infected Patients Treated with NFV, ddI, d4T and HU Abstract 558. Viral Load Rebound upon Discontinuation of d4T + ddI + NVP with or without Hydroxyurea (HU) during Primary HIV Infection (PHI) Abstract 559. Treatment of Primary HIV Infection with DDI, d4T, Nevirapine, and Hydroxyurea—A Pilot Study Abstract 560. Immunologic Characterization of a Cohort with Primary HIV Infection Treated with a Hydroxyurea-Containing Non-PI Antiretroviral Regimen Abstract 561. Comparison of Cell-Associated HIV-1 DNA and RNA in Triple-Drug-Treated Versus Untreated Persons with Primary HIV-1: Evidence for Persistent Viral Reservoirs Abstract 562. Screening and Diagnosis of Primary Immunodeficiency Virus Infection Abstract 563. Characterization of HIV-1 Isolates from Acute Retroviral Syndrome Abstract 564. Increased Seminal Shedding of HIV during Primary Infection Augments the Need for Earlier Diagnosis and Prevention Abstract 565. The Genotypic Basis of Moderately Reduced Susceptibility to Antiretroviral Drugs in Primary HIV Infection Abstract 566. Lack of Baseline Variability of Antivirogram Phenotyic Assay for Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance Abstract 567. Transmission of Dual and Triple-Class Drug-Resistant Viral Variants in Primary/Early HIV-1 Infection (PHI) in Montreal Abstract 568. HIV Postexposure Prophylaxis: Efficacy of HAART in Nonhuman Primate Model Abstract 569. CCR5 Heterozygosity Is Associated with Preserved HIV-Specific Cellular Immune Responses in Recent Seroconverters Abstract 570. Association of the CCR5D32 Mutation with Improved Response to Antiretroviral Therapy Commenced in Primary HIV Infection Abstract 571. An Antiviral Antibody (Ab) Response Occurs Early in Acute HIV Infection (AcHIV) Abstract 572. Suppression of Interleukin (IL)-12 Production by Acute HIV Infection and the Role of Other Cytokines Abstract 573. Weak Anti-HIV CD8+ T Cell Effector Activity in HIV-1 Primary Infection Abstract 574. CCR5+ CD4 and CD8 T Lymphocytes in Primary HIV-1 Infection Abstract 575. Massive Proliferation of CD8+ T Lymphocytes and Natural Killer (NK) Cells during Acute SIV Infection in Rhesus Macaques Abstract 576. Kinetics of SIV-Specific Cellular Immune Responses in SIV-Infected Neonatal Rhesus Macaques Abstract 577. Levels of Virus Replication, Cellular Immune Responses, and Availability of Proliferating CD4+ T Cells in Lymphoid Tissues during Primary SIV Infection Abstract 578. Analysis of HIV-1-Specific CD4+ T Cell Responses in HIV-1-Infected Individuals: A Concordance between Cytokine Release and Lymphoproliferation in Long-Term Nonprogressors (LTNP) Abstract 579. Detection of HIV-1-Specific-CD4 T Cells by ELISPOT in Patients on Prolonged Highly Active Antiretroviral Therapy (HAART) Abstract 580. The Occurrence of Opportunistic Infections (OIs) at Relatively High CD4 Levels Is Associated with an Antigen-Specific Absence of Lymphocyte Proliferative Responses (LPR) Abstract 581. Persistent Deficits in Cytomegalovirus (CMV)-Specific CD4+ T Cell Responses in HIV-1-Infected Subjects with Relapsing CMV Retinitis after Successful Highly Active Antiretroviral Therapy (HAART) Abstract 582. Flow Cytometric Analysis of HIV-1 Antigen-Specific CD4+ T Cell Proliferation in HIV-Infected Long-Term Survivors Abstract 583. Direct Measurement of Helper T Cells during Primary HIV Infection and after Treatment Abstract 585. Identification of Novel Helper T Lymphocyte Epitopes: Implications for HIV-1 Epitope-Based Vaccines Abstract 586. Analysis of the Functional HIV-1-Specific T-Cell Repertoire on HAART by ELISPOT Abstract 587. T-Cell Responses to HIV Antigens after Antiretroviral Treatment Abstract 588. Early Highly Active Antiretroviral Therapy for Acute HIV-1 Infection Preserves Immune Function of CD8+ and CD4+ T Lymphocytes Abstract 589. Designing and Assessing HIV Vaccines for Cross-Clade Immunogenicity Using Bio-Informatics Abstract 590. Cellular Immunity to HIV-1 Clades: Relevance to HIV-1 Vaccine Trials in Uganda Abstract 591. Modulation of TCR B Chain Repertoire Diversity and Decay Kinetics of HIV-Specific CTL after Initiation of HAART during Primary HIV Infection Abstract 592. HIV-Specific T Cell Gene Therapy Suppresses Viral Local Rebound in Subjects on Highly Active Antiretroviral Therapy (HAART) Abstract 593. Predominance of Nef-Specific CD8 Cell Responses in Acute HIV Infection and Persistence of HIV-Specific CD8 Memory Cells during Viral Suppression Abstract 594. Functional Studies of Antigen-Specific CD8+ T Cells Using a Combinatin of Tetramer and Intracellular Cytokine Staining Abstract 595. Longitudinal Analysis of HIV-1-Specific IFN-y Production in Unstimulated Mononuclear Cells of Highly HIV-1-Exposed, but Seronegative Women Abstract 596. Longitudinal HIV-1-Specific CD8+ T Cell Responses in Acute and Chronic HIV-Infected Subjects after Starting HAART Abstract 597. Impact of Early Highly Active Antiretroviral Therapy (HAART) on HIV-1-Specific Cytotoxic T Cell Responses in HIV-1-Infected Children Abstract 598. Human Immunodeficiency Virus Type-1 and Cytomegalovirus-Specific Cytotoxic T Lymphocytes (CTL) Can Persist at High Frequency in the Absence of Peripheral CD4+ T Cells Abstract 599. CD8+ T-Cell Subpopulations in HIV-Infected Children: Active Infection vs. Nonprogression of Infection vs. Suppressed Infection on HAART Therapy Abstract 600. Function and Phenotypic Analysis of Circulating HIV-Specific CD8 T Cells Abstract 601. MHC-I-Restricted HIV-Specific CD8 T Cell Responses in Children Chronically Infected with HIV-1 Abstract 602. Escape of HIV-1 from Cytotoxic T Lymphocytes In Vitro Abstract 603. Nef-Reactive Cytotoxic T Lymphocytes (CTLs) in an HIV-Exposed Health Care Worker (HCW) Abstract 604. Dynamics of Human Immunodeficiency Virus (HIV)-1-Specific and Epstein-Barr Virus-Specific CD8+ T Cells in the Course of HIV-1 Infection Abstract 605. Quantifying IFN-g-Secreting Cells in Exposed Uninfected Individuals Abstract 606. Maintenance of Large Numbers of Virus-Specific CD8+ T Cells in HIV-Infected Progressors and Long-Term Nonprogressors Abstract 607. Persistence of Large Clonal CD4+ T Cell Expansions without Responsiveness in HIV-Infected Patients on Long-Term HAART Abstract 608. Comparison of PCR and Flow Cytometry for Investigating Alterations in the TCR V b Repertoire in HIV-Infected Children Abstract 609. Influence of Disease Progression and Response to Antiretroviral Therapy (ART) on CD4 T Cell Repertoire in HIV-Infected Children Abstract 610. CD4+ T Cell Receptor Repertoire and HIV-Specific T-Helper Function in Patients Receiving Early Combination Therapy Abstract 611. CD4+ T Cell Repertoire Dynamics in Treated and Nontreated PHI Patients Abstract 612. Dynamics of T-Cell Receptor Repertoires in Lymphoid Compartments of Macaques Rectally Inoculated with SIVsmmPBj14 Abstract 613. Nuclear Import of HIV in T Cells Is Dependent on Topoisomerase IIa Expression Abstract 614. A Two-Step Model for Dimerization of Moloney Murine Sarcoma Virus Genomic RNA Abstract 615. A Proofreading-Like Mechanism Ensures Highly Accurate Reverse Transcription during the Initiation of HIV-1 (+) Srand Synthesis Abstract 616. Identification of Elements of tRNA Essential for Primer Selection and Use in HIV-1 Reverse Transcription Abstract 617. Morphologic Changes in HIV-1 Virions Secondary to Intra-Virion Reverse Transcription: Evidence Indicating That Reverse Transcription May Not Take Place within the Intact Viral Core Abstract 618. Site-Specific Incorporation of Nucleoside Analogs by HIV-1 Reverse Transcriptase and the Template Grip Mutant P157S Abstract 619. Mutations in the Flap Domain of the HIV Protease Can Compensate for M46F Abstract 620. Steady-State Protease Diversity in Untreated HIV-1-Infected Patients Abstract 621. Transduction Efficiency and Gene Expression from Integrase-Defective Lentiviral Hybrid Vectors Containing an Episomal Origin of Replication Abstract 623. Characterization of HIV-1 Integrase Inhibitors Abstract 624. The HERV-K Proviruses in All Humans Abstract 625. A Novel Inducible System to Study HIV-1 Vpr Function Abstract 626. Functional Implications of the Interaction of HIV-1 Vpr with a Fission Yeast Orthologue (Rhp23) of the Human Nucleotide Excision Repair Gene HHR23A Abstract 627. Nuclear Import and Export of HIV-1 Vpr Abstract 628. Interaction of HIV-1 Vpr Cellular Ligand hVIP/mov34 with HIV-2/SIV Vpr and Vpx Abstract 629. Functional Analysis of HIV-2/SIV Vpx: Identification of Determinants Essential for Subcellular Localization and Virion Packaging Abstract 630. The Generation and Application of a Doxycycline-Repressible, HIV-1 Nef Expression System Abstract 631. The Relationship between HIV-1 Nef and Adaptor Protein Complexes Examined by Confocal Fluorescence Microscopy Abstract 632. HIV Nef Interacts with Envelope Protein Via Gag Precursors: Impact on Viral Assembly and Infectivity Abstract 633. Nef Protein of HIV-1 and the Cellular Protein Sorting Machinery Abstract 634. The Effect of HIV-1 Nef on the Large-Scale Pattern of Cellular Gene Expression Abstract 635. Rescue of Vif-Negative Phenotype of Mutant HIV-1 Viruses from Nonpermissive Cells by Intravirion Reverse Transcription Abstract 636. Protection Against Human Immunodeficiency Virus Type 1 (HIV-1) by SV40-Mediated Delivery of Genes Interfering with HIV-1 Tat Abstract 637. Transcriptional Repression of the Human Immunodeficiency Virus Type-1 Long Terminal Repeat via Recruitment of Histone Deacetylase-1 Abstract 638. HIV-1 LTR Activation by the Bis-Peroxovanadium PTP Inhibitors: a Direct Role for the NFAT Transcription Factor Abstract 639. High-Affinity Rev-Binding RNA Molecules Selected In Vitro are Effective Inhibitors of HIV-1 Gene Expression and Replication Abstract 640. Overexpression of C-Myc Down-regulates Gene Expression of HIV by a Mechanism Unrelated to Apoptosis Abstract 641. Dual Infection of an Individual with Two Distinct HIV-1 Strains Reveals the First Biological Evidence in Favor of Synergism between HIV-1 Strains in Modulating Pathogenesis Abstract 642. In Vitro Evidence of HIV-2 Protection from Subsequent HIV-1 Infection L5 Timing the Origin of the HIV-1 Pandemic L6 Making Sense of Primate Lentiviral Accessory Gene Functions S25 HIV Transactivator Tat: A Model System for Eukaryotic Transcriptional Elongation S26 Intracellular Trafficking of HIV-1 Particles and Viral Proteins S28 HIV/AIDS in Africa: Why So Severe, Why So Heterogenous? S29 The San Francisco Postexposure Prevention Program: Lessons and Future Challenges S30 Is the Stage Being Set for a Resurgence in the HIV Epidemic Among Men Who Have Sex with Men? S31 Application of High Throughput, Qualitative Nucleic Acid Tests (NAT) for HIV/HCV in Blood Donor Screening, Diagnostic, and Public Health Settings S32 Drug Resistance and the Management of Treatment Failure S33 The Status of Salvage Therapy S34 The Prospect for New Agents in the Management of Treatment Failure